Home » Stocks » AXGT

Axovant Gene Therapies Ltd. (AXGT)

Nov 13, 2020 - Stock symbol was changed to SIOX
Stock Price: $2.10 USD 0.00 (0.00%)
Updated Nov 12, 2020 4:00 PM EST

Stock Price Chart

Key Info

Market Cap 84.71M
Revenue (ttm) n/a
Net Income (ttm) -53.17M
Shares Out 40.34M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Nov 12, 2020
Last Price $2.10
Previous Close $2.10
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.07 - 2.17
Day's Volume 0
52-Week Range 1.41 - 6.12

More Stats

Market Cap 84.71M
Enterprise Value 29.76M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 40.34M
Float 24.37M
EPS (basic) -1.90
EPS (diluted) -1.78
FCF / Share -1.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.44M
Short Ratio 0.65
Short % of Float 5.91%
Beta 1.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.69
Revenue n/a
Operating Income -51.45M
Net Income -53.17M
Free Cash Flow -63.44M
Net Cash 54.95M
Net Cash / Share 1.36
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -37.29%
ROE -120.92%
ROIC -3,363.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (7)

Buy 5
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.42*
(300.95% upside)
Low
7.00
Current: $2.10
High
12.50
Target: 8.42
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-69.17-127-213-180-133-21.05
Net Income-72.63-129-222-181-133-21.05
Shares Outstanding24.8116.1013.4212.3911.812.00
Earnings Per Share-2.93-8.02-16.51-14.56-11.28-10.56
Operating Cash Flow-67.47-134-190-112-53.35-0.68
Capital Expenditures-0.26-0.20-4.28-0.11-0.09-0.01
Free Cash Flow-67.73-134-195-112-53.44-0.69
Cash & Equivalents80.75107154213276-
Total Debt16.3944.1852.6851.44--
Net Cash / Debt64.3662.82102161276-
Assets93.681231612232821.12
Liabilities32.1266.4989.5097.7015.768.87
Book Value61.5656.2171.29125267-7.75
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Axovant Gene Therapies Ltd.
Country United Kingdom
Employees 38
CEO Pavan Cheruvu

Stock Information

Ticker Symbol AXGT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AXGT

Description

Axovant Gene Therapies, a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Sciences Ltd. and changed its name to Axovant Gene Therapies Ltd. in March 2019. Axovant Gene Therapies Ltd. was founded in 2014 and is based in London, the United Kingdom.